Berry Genomics Hits Day High with 10.03% Surge in Strong Intraday Performance

Berry Genomics Co., Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a significant uptick in its stock price, gaining 10.03% on August 21, 2026. The stock reached an intraday high of CNY 10.31, marking a notable performance against the backdrop of the China Shanghai Composite, which saw a minimal increase of 0.04% on the same day. Over the past week, Berry Genomics has shown a robust performance with a 12.43% rise, and its monthly performance stands at an impressive 34.07%. However, the company has faced challenges in the longer term, with a one-year performance decline of 28.15% and a five-year drop of 58.26%. Despite the recent gains, key financial metrics indicate underlying issues, including a low Return on Capital Employed (ROCE) of 1.32% and a concerning trend in net sales, which have decreased at an annual rate of 9.29% over the last five years. The company’s market capitalization is currently CNY 3,208 million, reflecting its small-cap status within the industry.